Literature DB >> 18539340

Prediction of antidepressant response in both 2.25xthreshold RUL and fixed high dose RUL ECT.

James N Kimball1, Peter B Rosenquist, Aaron Dunn, W Vaughn McCall.   

Abstract

UNLABELLED: Some forms of electroconvulsive therapy (ECT) can result in generalized seizures that lack efficacy, therefore physiological markers of treatment adequacy would be helpful. EEG measures of seizure quality, such as EEG regularity and post-ictal suppression, have largely supplanted seizure duration as a marker for seizure adequacy, yet no predictive algorithm has gained wide clinical acceptance. Electrographic seizure durations of less than 25 s still prompt re-stimulation in many settings. We re-examined the utility of EEG seizure duration and other measures of EEG seizure as predictors of antidepressant response to right unilateral (RUL) ECT.
METHODS: Seventy-two adult patients with major depression were randomized to either titrated RUL ECT at 2.25 times initial seizure threshold or RUL ECT at a fixed dose of 403 mC. Intent-to-treat responder status (defined by 60% reduction in HRSD scores and final score of 12 or less after the last RUL ECT session) was identified as the dependent variable in a nominal logistic regression model including EEG seizure quality candidate variables, controlled for age and gender.
RESULTS: A model including EEG seizure duration, EEG regularity, post-ictal suppression, age and gender and randomization status was significantly predictive of intent-to-treat responder status at treatment 2 (R2=.21 p<.003; N=66) and treatment 4 (R2=.27 p<.0004; N=67). The model remained significant at these time points even when randomization status (titrated moderately suprathreshold vs. high fixed dosage) was removed (Treatment 2: R2=.18 p<.007; Treatment 4: R2=.23 p<.0007).
CONCLUSION: EEG markers of seizure adequacy, including EEG seizure duration, are modestly predictive of antidepressant response for both titrated moderately suprathreshold and high fixed dosage RUL ECT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18539340     DOI: 10.1016/j.jad.2008.03.030

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

1.  A novel Seizure Quality Index based on ictal parameters for optimizing clinical decision making in electroconvulsive therapy. Part 1: development.

Authors:  Laura Kranaster; Suna Su Aksay; Jan Malte Bumb; Carolin Hoyer; Christine Jennen-Steinmetz; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-06-06       Impact factor: 5.270

2.  Electroconvulsive therapy can benefit from controlled hyperventilation using a laryngeal mask.

Authors:  Martina Haeck; Benjamin Gillmann; Hildegard Janouschek; Michael Grözinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-08-28       Impact factor: 5.270

3.  A Retrospective Study of Postictal Suppression during Electroconvulsive Therapy.

Authors:  Virginie Moulier; Julien Guehl; Emilie Evêque-Mourroux; Pierre Quesada; Maud Rothärmel
Journal:  J Clin Med       Date:  2022-03-05       Impact factor: 4.241

4.  Changes in seizure duration during acute course electroconvulsive therapy.

Authors:  James Luccarelli; Thomas H McCoy; Stephen J Seiner; Michael E Henry
Journal:  Brain Stimul       Date:  2021-06-11       Impact factor: 9.184

5.  Narp Mediates Antidepressant-Like Effects of Electroconvulsive Seizures.

Authors:  Andrew D Chang; Punit V Vaidya; Edward P Retzbach; Sunho J Chung; Urian Kim; Kathryn Baselice; Kristen Maynard; Alec Stepanian; Melissa Staley; Lan Xiao; Ashley Blouin; Sungho Han; JongAh Lee; Paul F Worley; Kellie L Tamashiro; Barbara L Hempstead; Keri Martinowich; Mary Ann Wilson; Jay M Baraban; Irving M Reti
Journal:  Neuropsychopharmacology       Date:  2017-10-20       Impact factor: 8.294

6.  Influence of valproate on the required dose of propofol for anesthesia during electroconvulsive therapy of bipolar affective disorder patients.

Authors:  Gökben Hızlı Sayar; Gül Eryılmaz; Siban Semieoğlu; Eylem Ozten; Işıl Göğcegöz Gül
Journal:  Neuropsychiatr Dis Treat       Date:  2014-03-04       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.